Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 104 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infection or Inflammation Clear all

Conditions: Lung Inflammation, Experimental Lung Inflammation
Interventions: Ozone Exposure, Clean air (0.0 ppm ozone); Other
Lead sponsor: Environmental Protection Agency (EPA); Federal
Eligibility: 18 Years to 35 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Panuveitis
Interventions: LFG316, Conventional Therapy; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 6
States / cities: Golden, Colorado • Marietta, Georgia • Cambridge, Massachusetts + 3 more

Conditions: Sepsis
Interventions: CNA Rapid Sepsis Dx; Diagnostic Test
Lead sponsor: Robert Ehrman; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Birmingham, Alabama • Detroit, Michigan • New York, New York

Conditions: Laceration, Abscess
Interventions: Nitrous Oxide; Drug
Lead sponsor: New York City Health and Hospitals Corporation; Other
Eligibility: 3 Years to 12 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Sepsis, Septic Shock
Interventions: vasopressin - early initiation, vasopressin - standard initiation; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Mucocutaneous Ulcer, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Large B-Cell Lymphoma With 11q Aberration, Large B-Cell Lymphoma With IRF4 Rearrangement, Plasmablastic Lymphoma, Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Primary Effusion Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Gray-Zone Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent Lymphomatoid Granulomatosis, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Gray-Zone Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions: Nivolumab, Varlilumab; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 33
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 24 more

Conditions: Necrotizing Enterocolitis, Sepsis
Interventions: Fortified Pasteurized Donor Human Milk supplement, Preterm Formula supplement; Behavioral
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 0 Years to 96 Hours
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Infections, Infected Wound, Nonunion of Fracture, Injury Leg, Amputation, Internal Fixation; Complications, Infection or Inflammation, Fracture, Lower Extremity Fracture, Antibiotic Side Effect
Interventions: Standard of Care PO (oral) antibiotics, Standard of Care Intravenous (IV) antibiotics; Drug
Lead sponsor: Major Extremity Trauma Research Consortium; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 13
States / cities: Indianapolis, Indiana • Baltimore, Maryland • Minneapolis, Minnesota + 9 more

Conditions: Sepsis, Congenital Diaphragmatic Hernia, Neonatal Cardiopulmonary Failure
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: Up to 2 Months
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Salt Lake City, Utah

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Months to 52 Months
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe), COVID-19 Pneumonia
Interventions: Mesenchymal stromal cells, Placebo; Biological · Other
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Pittsburgh, Pennsylvania

Conditions: New Onset Atrial Fibrillation, Severe Sepsis, Septic Shock
Interventions: Amiodarone; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Severe Sepsis, Septic Shock
Interventions: Not listed
Lead sponsor: Brahms AG; Industry
Eligibility: 18 Years and older
Enrollment: 858 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 13
States / cities: Sacramento, California • Chicago, Illinois • Boston, Massachusetts + 7 more

Conditions: Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
Interventions: Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo; Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 19
States / cities: Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more

Conditions: Osteoarthritis, Knee Infection, Prosthetic Joint Infection, Complications; Arthroplasty, Infection or Inflammation, Complications; Arthroplasty
Interventions: Static Spacer, Articulating Spacer; Procedure
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Uveitis
Interventions: Dose 2 gevokizumab; Drug
Lead sponsor: XOMA (US) LLC; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 33
States / cities: Chandler, Arizona • Phoenix, Arizona • Beverly Hills, California + 30 more

Conditions: Cardiovascular Disease, Healthcare Associated Infectious Disease, Sternal Superficial Wound Infection, Deep Sternal Infection, Mediastinitis, Thoracotomy, Conduit Harvest or Cannulation Site, Sepsis, Pneumonia
Interventions: There is no intervention. The investigators are interviewing cardiac surgery staff with knowledge of infection prevention.; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Stroke (CVA) or TIA, Diabetes, Asthma (Diagnosis), COPD (Chronic Obstructive Pulmonary Disease), Sepsis, Hypertension, Heart Failure, Pneumonia, Urinary Tract Infection (Diagnosis), Chest Pain, Psychiatric Disorder, Sickle Cell Disease (SCD)
Interventions: Not listed
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 30,486 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Oropharyngeal Candidiasis, Candidemia, Invasive Candidiasis, Esophageal Candidiasis
Interventions: Micafungin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 7
States / cities: Los Angeles, California • Orange, California • Kansas City, Missouri + 4 more

Conditions: Brain Injury, Central Nervous System Degenerative Disorder, Central Nervous System Infectious Disorder, Central Nervous System Vascular Malformation, Hemorrhagic Cerebrovascular Accident, Ischemic Cerebrovascular Accident, Primary Brain Neoplasm, Brain Cancer, Brain Tumors
Interventions: Ferumoxytol, Tissue Analysis, Magnetic Resonance Imaging; Drug · Other · Procedure
Lead sponsor: Michael Iv; Other
Eligibility: 2 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Candidiasis
Interventions: Eraxis (anidulafungin), Diflucan (fluconazole), Vfend (voriconazole); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 39
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 25 more

Conditions: Infection, Bacteremia
Interventions: Telavancin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Severe Sepsis or Septic Shock
Interventions: Calcitriol, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 23
States / cities: Los Angeles, California • Menlo Park, California • San Diego, California + 14 more

Search by objective public record fields.

Pulmonary and Inflammatory Responses Following Exposure to a Low Concentration of Ozone or Clean Air at Rest

Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,

Preclinical Detection of Sepsis Early in Hospitalized Patients Following Surgery, Injury or Severe Illness

Nitrous Oxide Use in Minor Procedures

Early Versus Late Adjunctive Vasopressin in Septic Shock

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Study of the Relationship Between Feeding and Late Onset Sepsis and/or Necrotizing Enterocolitis in Low Birth Weight Infants

PO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation

Inflammatory Cytokine Quantification in Infants

Using MRI to Observe Lung Changes in Infants With CF Compared to Infants Without CF

Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)

Use of Amiodarone in Atrial Fibrillation Associated With Severe Sepsis or Septic Shock

Procalcitonin Monitoring Sepsis Study

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

Articulating Versus Static Antibiotic Loaded Spacers for the Treatment of Prosthetic Knee Infection

An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data

Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery (HAI)_2

Risk Factors, Costs, and Impacts of ED Boarding

Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS

Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

Randomized Controlled Trial of Calcitriol vs. Placebo Among Critically-ill Patients With Sepsis

HIV in Specific Parts of the Body of Patients Who Are Changing or Starting Potent Anti-HIV Drugs